Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Am J Gastroenterol. 2014 Jul 29;109(9):1484–1492. doi: 10.1038/ajg.2014.193

Table 3.

Operative findings of subjects who underwent curative surgical resection of pancreatic cancer based on DM status.

Variable DM (N=275) Non-DM (N=213) Total (N=488) p-value*
Site of Pancreatic Mass 0.063
Head/uncinate 222 (81.6%) 146 (71.2%) 368 (77.1%)
head and body 12 (4.4%) 9 (4.4%) 21 (4.4%)
body 12 (4.4%) 14 (6.8%) 26 (5.5%)
body and tail 5 (1.8%) 9 (4.4%) 14 (2.9%)
tail 21 (7.7%) 27 (13.2%) 48 (10.1%)
Operation Type 0.005
Pancreaticoduodenectomy 222 (80.7%) 160 (75.1%) 382 (78.3%)
Distal pancreatectomy 36 (13.1%) 48 (22.5%) 84 (17.2%)
Total pancreatectomy 17 (6.2%) 5 (2.3%) 22 (4.5%)
Portal or Superior Mesenteric Vein Reconstruction 0.208
Yes 49 (18.8%) 24 (14.1%) 73 (16.9%)
Resection Status 0.829
R0 (negative margins) 221 (81.0%) 166 (80.2%) 387 (80.6%)
R1 (microscopically positive margins) 42 (15.4%) 34 (16.4%) 76 (15.8%)
R2 (grossly positive margins) 5 (1.8%) 2 (1.0%) 7 (1.5%)
Maximum tumor dimension (cm) 0.002
Mean (SD) 3.59 (1.42) 3.27 (1.69) 3.45 (1.55)
Tumor Grade 0.012
Well differentiated 0 (0.0%) 2 (1.0%) 2 (0.4%)
Moderately differentiated 36 (13.7%) 47 (23.9%) 83 (18.0%)
Poorly differentiated 190 (72.2%) 126 (64.0%) 316 (68.7%)
Undifferentiated 37 (14.1%) 22 (11.2%) 59 (12.8%)
Number of Positive Nodes 0.317
Mean (SD) 2.15 (3.85) 2.06 (3.96) 2.11 (3.90)
Ratio of Positive Nodes/Total Number 0.306
Mean (SD) 0.15 (0.21) 0.18 (0.48) 0.16 (0.35)
Stage at Diagnosis 0.907
I 48 (17.6%) 36 (17.2%) 84 (17.4%)
II 220 (80.6%) 168 (80.4%) 388 (80.5%)
III 5 (1.8%) 5 (2.4%) 10 (2.1%)
Adjuvant Chemotherapy 0.752
Yes 230 (85.2%) 169 (86.2%) 399 (85.6%)
Adjuvant Radiotherapy 0.122
Yes 189 (69.2%) 130 (62.5%) 319 (66.3%)
*

P-values for categorical variables were calculated using a Pearson chi-square test. A Kruskal-Wallis test was used for continuous variables.

HHS Vulnerability Disclosure